系列:实用临床试验与真实世界证据:第6篇:真实世界中的结局指标
本文为方法学系列文章第6篇,讨论实用临床试验结局指标的类型与适用性、测量设计选择及其影响与挑战。文章指出实用试验应聚焦患者、临床实践和治疗选择相关的结局,优先使用常规收集数据,避免将替代终点作为主要结局,并建议在预期高偏倚或高变异时考虑标准化与盲法评估。
要点
- 实用试验应选择与患者、临床实践和治疗决策相关的结局指标。
- 结局测量不应干扰真实临床实践,优先使用常规收集的结局数据。
- 典型结局包括死亡、发病率、功能状态、健康和资源使用,通常避免替代终点作为主要结局。
核心结论
- 实用试验应反映真实临床实践中患者所见的比较治疗效果,结局选择应与决策相关且在目标情境下可行。
研究设计与样本
- 本文为方法学系列文章第6篇,讨论实用试验中结局指标的类型、测量设计选择及其影响与挑战。
主要发现
- 实用试验应聚焦患者、临床实践和治疗选择相关的结局,测量不应干扰真实临床实践以确保结果可推广。
- 典型结局包括死亡、发病率、功能状态、健康和资源使用,通常避免将替代终点作为主要结局。
- 应在相关时间范围内测量结局并获得有效且精确的结果;开放标签试验中较客观的结局可减少偏倚。
关键数值与推荐
- 当预期高偏倚风险或高变异时,应考虑降低偏倚或提高精确度的方法,如标准化和结局评估盲法。
临床怎么用
- 结局选择应与所有利益相关方尽早讨论,以确保研究结果对临床实践决策的相关性和研究的可执行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Results from pragmatic trials should reflect the comparative treatment effects encountered in patients in real-life clinical practice to guide treatment decisions. Therefore, pragmatic trials should focus on outcomes that are relevant to patients, clinical practice, and treatment choices. This sixth article in the series (see Box) discusses different types of outcomes and their suitability for pragmatic trials, design choices for measuring these outcomes, and their implications and challenges. Measuring outcomes in pragmatic trials should not interfere with real-world clinical practice to ensure generalizability of trial results, and routinely collected outcomes should be prioritized. Typical outcomes include mortality, morbidity, functional status, well-being, and resource use. Surrogate endpoints are typically avoided as primary outcome. It is important to measure outcomes over a relevant time horizon and obtain valid and precise results. As pragmatic trials are often open label, a less subjective outcome can reduce bias. Methods that decrease bias or enhance precision of the results, such as standardization and blinding of outcome assessment, should be considered when a high risk of bias or high variability is expected. The selection of outcomes in pragmatic trials should be relevant for decision making and feasible in terms of executing the trial in the context of interest. Therefore, this should be discussed with all stakeholders as early as feasible to ensure the relevance of study results for decision making in clinical practice and the ability to perform the study.
引用
- Welsing PM, Oude Rengerink K, Collier S, et al. Series: Pragmatic trials and real world evidence: Paper 6. Outcome measures in the real world. J Clin Epidemiol. 2017. PMID: 28502810. doi:10.1016/j.jclinepi.2016.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。